These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 37828711

  • 1. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
    Packnett ER, Winer IH, Oladapo A, Wojdyla M.
    Hum Vaccin Immunother; 2023 Aug; 19(2):2252289. PubMed ID: 37828711
    [Abstract] [Full Text] [Related]

  • 2. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
    Packnett ER, Winer IH, Larkin H, Oladapo A, Gonzales T, Wojdyla M, Goldstein M, Smith VC.
    Hum Vaccin Immunother; 2022 Nov 30; 18(6):2140533. PubMed ID: 36412253
    [Abstract] [Full Text] [Related]

  • 3. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.
    Fergie J, Goldstein M, Krilov LR, Wade SW, Kong AM, Brannman L.
    Hum Vaccin Immunother; 2021 May 04; 17(5):1536-1545. PubMed ID: 33090914
    [Abstract] [Full Text] [Related]

  • 4. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM, Krilov LR, Fergie J, Goldstein M, Diakun D, Wade SW, Pavilack M, McLaurin KK.
    Am J Perinatol; 2018 Jan 04; 35(2):192-200. PubMed ID: 28881376
    [Abstract] [Full Text] [Related]

  • 5. Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.
    Kong AM, Winer IH, Zimmerman NM, Diakun D, Bloomfield A, Gonzales T, Fergie J, Goldstein M, Krilov LR.
    Am J Perinatol; 2023 Oct 04; 40(14):1529-1536. PubMed ID: 34704241
    [Abstract] [Full Text] [Related]

  • 6. Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016.
    Goldstein M, Krilov LR, Fergie J, McLaurin KK, Wade SW, Diakun D, Lenhart GM, Bloomfield A, Kong AM.
    Am J Perinatol; 2018 Dec 04; 35(14):1433-1442. PubMed ID: 29920638
    [Abstract] [Full Text] [Related]

  • 7. Unintended Consequences Following the 2014 American Academy of Pediatrics Policy Change for Palivizumab Prophylaxis among Infants Born at Less than 29 Weeks' Gestation.
    Goldstein M, Krilov LR, Fergie J, Brannman L, Wade SW, Kong AM, Ambrose CS.
    Am J Perinatol; 2021 Aug 04; 38(S 01):e201-e206. PubMed ID: 32299107
    [Abstract] [Full Text] [Related]

  • 8. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
    Krilov LR, Fergie J, Goldstein M, Brannman L.
    Am J Perinatol; 2020 Jan 04; 37(2):174-183. PubMed ID: 31430818
    [Abstract] [Full Text] [Related]

  • 9. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
    Anderson EJ, DeVincenzo JP, Simões EAF, Krilov LR, Forbes ML, Pannaraj PS, Espinosa CM, Welliver RC, Wolkoff LI, Yogev R, Checchia PA, Domachowske JB, Halasa N, McBride SJ, Kumar VR, McLaurin KK, Rizzo CP, Ambrose CS.
    Am J Perinatol; 2020 Mar 04; 37(4):421-429. PubMed ID: 30991438
    [Abstract] [Full Text] [Related]

  • 10. Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan.
    Chi H, Chung CH, Lin YJ, Lin CH.
    PLoS One; 2018 Mar 04; 13(5):e0197410. PubMed ID: 29746578
    [Abstract] [Full Text] [Related]

  • 11. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
    Priante E, Tavella E, Girardi E, Militello MA, Mardegan V, Maule MM, Dall'Agnola A, Baraldi E, Manzoni P.
    Am J Perinatol; 2019 Jul 04; 36(S 02):S77-S82. PubMed ID: 31238365
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants.
    DeVincenzo JP, Ambrose CS, Makari D, Weiner LB.
    Hum Vaccin Immunother; 2016 Apr 02; 12(4):971-5. PubMed ID: 26889568
    [Abstract] [Full Text] [Related]

  • 13. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R, Wolfler A, Picone S, Rossi GA, Gualberti G, Merolla R, Del Vecchio A, Villani A, Midulla F, Dotta A.
    Ital J Pediatr; 2019 Nov 09; 45(1):139. PubMed ID: 31706338
    [Abstract] [Full Text] [Related]

  • 14. Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS).
    Fergie J, Suh M, Jiang X, Fryzek JP, Gonzales T.
    J Infect Dis; 2022 Apr 01; 225(7):1197-1204. PubMed ID: 32691037
    [Abstract] [Full Text] [Related]

  • 15. Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics.
    Krilov LR, Anderson EJ.
    J Perinatol; 2020 Aug 01; 40(8):1135-1144. PubMed ID: 32499597
    [Abstract] [Full Text] [Related]

  • 16. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
    McLaurin KK, Farr AM, Wade SW, Diakun DR, Stewart DL.
    J Perinatol; 2016 Nov 01; 36(11):990-996. PubMed ID: 27490190
    [Abstract] [Full Text] [Related]

  • 17. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
    Keary IP, Ravasio R, Fullarton JR, Manzoni P, Lanari M, Paes BA, Carbonell-Estrany X, Baraldi E, Tarride JÉ, Rodgers-Gray B.
    PLoS One; 2023 Nov 01; 18(8):e0289828. PubMed ID: 37561741
    [Abstract] [Full Text] [Related]

  • 18. SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
    Anderson EJ, Krilov LR, DeVincenzo JP, Checchia PA, Halasa N, Simões EA, Domachowske JB, Forbes ML, Pannaraj PS, McBride SJ, McLaurin KK, Kumar VR, Ambrose CS.
    Am J Perinatol; 2017 Jan 01; 34(1):51-61. PubMed ID: 27233106
    [Abstract] [Full Text] [Related]

  • 19. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
    Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS.
    Hum Vaccin Immunother; 2014 Jan 01; 10(10):2789-94. PubMed ID: 25483663
    [Abstract] [Full Text] [Related]

  • 20. Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab.
    Manzoni P, Baraldi E, Luna MS, Tzialla C.
    Am J Perinatol; 2022 Dec 01; 39(S 01):S7-S13. PubMed ID: 36307092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.